## SRI VENKATESWARA COLLEGE OF PHARMACY



(Approved by AICTE & PCI, New Delhi, Permanently Affiliated to JNTUA, Ananthapuramu Accredited by NAAC, Bengaluru & NBA, New Delhi for UG Programme under Tier-II Recognized under section 2(f) & 12(B) of UGC Act, 1956 **Recognized Research Centre for Pharmaceutical Sciences by INTUA** Recognized In-House R & D by DSIR, New Delhi, DST – FIST Sponsored Institute) **RVS NAGAR, TIRUPATI ROAD, CHITTOOR – 517127, A.P.** 

# FARMACIA PRATICA LETTRE

**News Letter from Department of Pharmacy Practice** 

July - Sep. 2017 Vol. I. Issue III

#### Patron

Dr. Ravuri Venkataswamy Chairman SV Group of Institutions

#### **Co-Patron**

Mr. Ravuri Srinivas Vice Chairman SV Group of Institutions

Advisory Board

Dr. Shalini, MBBS, MD

Dr. L.C. Obulesu, MD Dean, RVS Institue of Medical Sciences

Dr. M.R. Gavathri Director, Quest Life Sciences

Dr. Paul Ravikumar, MS (ENT) Medical Superintendent, Govt Hospital, CTR.

Editor-in-Chief

Dr. K. Bhaskar Reddy, M.Pharm, Ph.D Prinicpal, Sri Venkateswara College of Pharmacy

**Editor** Dr. K. Dhivya, Pharm.D **Editorial Board** Dr. Lakshmi Siyasubramanian, M. Pharm, Ph.D Dr. S. Hemalatha, M. Pharm, Ph.D Dr. A. Saravanakumar, M. Pharm, Ph.D Dr. M. Rupesh Kumar, M. Pharm, Ph.D Dr. K. Kavitha, M. Pharm, Ph.D Dr. D. Jothieswari, M.Pharm, Ph.D Dr. Mohammad Badrud Duza Dr. Aleem Sarwar, Pharm.D. Dr. Raja Babu K., Pharm.D. **Student Editors** K. Bhargav, V year, Pharm.D. V.K. Sharuk, IV year, Pharm.D A. Ammajan, III year, Pharm.D

D. Durga Prasad, II year, Pharm.D

Shreya Suresh, II year, Pharm.D

#### **Principal's Cubicle**

In pursuits of continued academic excellence, SVCOP is ready with another issue of "FARMACIA PRACTICA LETTRE" from the department of Pharmacy Practice.



This would serve as a worthy piece of information in the field of pharmaceutical sciences. The motto behind publishing our newsletter is to enlighten the minds and make the people connected with the current medical updates which would definitely help them in creating a tight knot with prevailing health care system. I am glad to announce that first issue of our newsletter became a great success and the whole credit goes to the enthusiastic students as well as the faculty whose whole heart commitment deserves a big applause. In addition, our students were actively engaged in an awareness programme on "Antimicrobial Resistance Awareness Walk" conducted by AP Pharmacy council and its impact on the society was remarkable. Our institution is marching forward in creating a better tomorrow by providing a better healthcare services to the nation.

> **Dr. K. Bhaskar Reddy** Principal Sri Venkateswar College f Pharcmay

## In the Current Issue

- Hiccups-the involuntary action
- News update
- New drug profile
- Answers to the puzzle published in previous issue
- Departmental activities .

## FARMACIA PRATICA LETTRE

News Letter from Department of Pharmacy Practice

July - Sep.2017 Vol. I. Issue III

### Mini Reviews

#### **Hiccups-** The Involuntary Action

#### NIHAN ANWAR, II PHARM-D

The official medical term of "Hiccups" is **Singultus** (Latin word) which means **"To catch one's breath while crying".** A hiccup is produced by an amalgamation of two separate involuntary actions. First the muscle in the diaphragm contracts which makes us gasp more air than we would actually need in a normal inhalation. Then the glottis (a flap of skin which blocks airway to the lung) culminates immediately in about 35 milliseconds after the mass inhalation.

The "Hiccup sound" which we get is due to the closure of the glottis. Among all the mammals, humans are the one that hiccup more. Babies hiccup more than the adults and even the fetuses hiccup in the womb. *Remedies for Hiccups* are being tested. Rapid swallowing of water or breathing into a paper bag could retard the hiccups. Because both of the remedies release calcium ions due to which the nervous system activity is terminated. These activities could implicate muscle spasms. The record has been made by an incogitable man named "CHARLES OSBORNE" who hiccupped from 1922 to 1990. His hiccups astounded the doctors, which continued until he was 96 years and at last he got relief from his hiccups only a year before his death at the age of 97.

There's **no real reason** revealed for hiccupping for humans and it is yet to be figure of !!!

### News Update

#### FDA Improves Access to Reports of Adverse Drug Reactions

Rakesh Kumar Patel, III PHARM-D

The U.S. Food and Drug Administration today launched a new user-friendly search tool that improves access to data on adverse events associated with drug and biologic products through the FDA's Adverse Event Reporting System (FAERS) on September 28, 2017. The tool is designed to make it easier for consumers, providers, and researchers to access this information. "The FDA is committed to fully informing patients and providers of adverse events reported with medical products and this enhanced portal now provides patients, doctors and others with easier access to the data they are interested in." The new dashboard enables users to search for and organize data by criteria such as drug/biological product, age of the patient, type of adverse event, year the adverse event occurred, or within a specific timeframe. In addition to making it easier for consumers to search for adverse events reported with drug or biologic products, the FDA hopes the increased transparency will spur the submission of more detailed and complete reports from consumers, health care professionals and others, by making it easier for people to see other reports that the FDA receives, and search the database for similar observations. The FDA uses FAERS for surveillance, such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance with reporting regulations and responding to outside requests for information. The reports in FAERS are evaluated by clinical reviewers in the FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research to monitor the safety of products after they are marketed. If a potential safety concern is identified in FAERS, further evaluation is performed. While the FAERS dashboard now offers stakeholders many more ways of searching for and organizing data on adverse events reported to the FDA for many drug and biologic products, there remain limitations to the data. For example, while FAERS contains reports on adverse events associated with a particular drug or biologic, this does not mean that the drug or biologic caused the adverse event. Importantly, the FAERS data by themselves are not an indicator of the safety profile of the drug or biologic. Patients should still talk to their health care professional if they have any concerns regarding their medications. In addition to the FAERS database for drugs and biologics, the agency has adverse event reporting programs and databases for foods, dietary supplements, and cosmetics (CFSAN Adverse Event Reporting System, or "CAERS"), medical devices (Manufacturer and User Facility Device Experience, or "MAUDE") and vaccines (Vaccine Adverse Event Reporting System, or "VAERS" that the FDA co-manages with the Centers for Disease Control and Prevention).

# FARMACIA PRATICA LETTRE

**News Letter from Department of Pharmacy Practice** 

July - Sep.2017 Vol. I. Issue III


**Drug Profile** 

#### S. R. SADIYA PERVAZE, IV PHARM-D

| Drug Name (Generic) | L- GLUTAMINE ORAL<br>POWDER   | INOTUZUMAB/OZOGAMICIN   |
|---------------------|---|---|
| Company             | Emmaus life sciences  | Pfizer  |
| Approval Status     | July 2017   | August 2017   |
| Specific Treatment  | Sickle cell disease   | Relapsed or refractory B – cell precursor acute lymphoblastic leukemia  |
| Therapeutic Area    | Hematology  | Hematology  |
| Dosage              | -Orally twice per day<br>-Dose based on body weight<br>Less than 30kg: 5g<br>30 to 65kg: 10g<br>Greater than 65kg: 30g  | <ul> <li>For all patients 1.8 mg /m2 per cycle</li> <li>Day 1 - (0.8 mg /m2)</li> <li>Day 8 - (0.5 mg /m2)</li> <li>Day 15 - (0.5 mg /m2)</li> </ul>  |
| Mechanism of Action | Endari (l- glutamine oral powder)<br>reduces oxidant damage to red blood<br>cells by improving the redox potential<br>of nicotinamide adenine dinucleotide<br>(NAD) a coenzyme that has been<br>identified as the primary regulator<br>of oxidation | Besponsa is a CD22 directed antibody<br>drug conjugate. N acetyl gamma<br>calicheamicin is a cytotoxic agent that is<br>covalently attached to antibody. Non<br>clinical data suggest that the anticancer<br>activity of Besponsa is due to binding of<br>ADC to CD22. The intracellular release<br>of N – acetyl –gamma – calicheamicin<br>dimethyl hydrazide via hydrolytic<br>cleavage of the linker activation of –<br>acetyl gamma – calicheamicin dimethyl<br>hydrazide induces double strand DNA<br>breaks, induces cell cycle arrest and<br>apoptotic cell death. |
| AvailableBrands     | Endari, Glutasolve, Nutrestore,   | Besponsa  |
|                     | SYMPT –X G.1  |   |

### ANSWER TO THE CROSSWORD PUZZLE (PREVIOUS ISSUE)

**B SONIA, III PHARM-D** 



### News Letter from Department of Pharmacy Practice

July - Sep.2017 Vol. I. Issue III

| Across  | Down   |
|---|--|
| <ul> <li>3 Combination drug made up of amlodipine</li> <li>besylate/atorvastatin calcium</li> <li>5 Brand name of atorvastatin</li> <li>6 Brand name of conjugated estrogen</li> </ul>  | <ol> <li>Brand name of esomeprazole</li> <li>Inhaler form of mometasone</li> <li>Generic name of catapres</li> </ol>   |
| <ul><li>7 Generic name of trileptal</li><li>9 Generic name of celebrex</li><li>10 Generic name of dalmane</li></ul>   | 4 Brand name of fluticasone nasal spray<br>5 Brand name of metoprolol tartrate<br>8 Generic name of elavil   |
| <ul> <li>11 Generic name of pravachol</li> <li>13 Brand name of metformin ER 1000mg (OSM)</li> <li>14 Generic name of keppra</li> <li>18 Generic name of maxidex</li> <li>20 Brand name of clarithromycin</li> <li>21 Brand name of ceftriaxone</li> <li>22 Brand name of hydroxyzine chloride</li> </ul> | <ul> <li>12 Brand name of tamsulosin</li> <li>13 Inhaler form of fluticasone</li> <li>15 Brand name of quetiapine</li> <li>16 Brand name of diclofenac potassium</li> <li>17 Generic name of foradil</li> <li>19 Combination drug made up of dipyridamole and aspirin</li> </ul> |
|   |  |

## DEPARTMENTAL ACTIVITIES One Day National Seminar on "Current Trends in Pharmaceutical Sciences"

One day national seminar was organized on "Current Trends in Pharmaceutical Sciences" on 25/09/2017. The program was aimed to inculcate knowledge to the participants in the concepts of Pharmaceutics, Pharmacokinetics and Pharmacy Practice.



## **Pharmacists Day Celebrations**

World Pharmacists Day is celebrated on September  $25^{th}$  of every year. The day aimed in encouraging the activities to promote and support the role of the pharmacist in improving health in every nook and corner of the world. Many on stage and off stage events like singing, dancing, essay writing, elocution, debate, oral and poster presentations etc.were conducted to showcase our student's talents.



Suggestions & Comments may Kindly be sent to Editorial Board, Dept. of Pharmacy Practice, SVCOP, Chittor. Phone : 7729999181 Email. : editorsvcopnewsletter@svcop.in